Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions

NCT06753318 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 716

Last updated 2024-12-31

No results posted yet for this study

Summary

This clinical trial aims to learn if a multimodal artificial intelligence (AI) model can enhance the diagnosis of pancreatic solid lesions. The main questions it aims to answer are:

1. Does the AI model enhance the diagnostic performance of endoscopists in diagnosing pancreatic solid lesions?
2. Does the addition of interpretability analysis further improve the diagnostic performance of the assisted endoscopists? Researchers will compare the diagnostic performance of endoscopists with or without the assistance of the AI model.

Participants will:

1. Their clinical data will be prospectively collected.
2. They will be randomized to the AI-assist group and the conventional diagnosis group.

Conditions

  • Pancreatic Cancer
  • Pancreatitis
  • Pancreatic Neuroendocine Neoplasms (pNETs)
  • Autoimmune Pancreatitis
  • Solid Pseudopapillary Neoplasm of the Pancreas

Interventions

DIAGNOSTIC_TEST

The assistance of the Joint-AI model

Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis

DIAGNOSTIC_TEST

The assistance of the interpretable Joint-AI model

Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis

Sponsors & Collaborators

  • Beijing Union Hosptial

    collaborator UNKNOWN
  • Affiliated Drum Tower Hospital of Nanjing University Medical School

    collaborator UNKNOWN
  • Shanghai Longhua Hospital

    collaborator UNKNOWN
  • Beijing Friendship Hospital

    collaborator OTHER
  • Qilu Hospital of Shandong University

    collaborator OTHER
  • Sir Run Run Shaw Hospital

    collaborator OTHER
  • Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06753318 on ClinicalTrials.gov